李-弗劳门尼综合征
癌症
肺癌
家族史
生殖系
肉瘤
内科学
医学
肿瘤科
生物
遗传学
基因
种系突变
病理
突变
作者
Panwen Tian,Xiaoyan Zhang,Sheng Yang,Yu Fang,Hongling Yuan,Wěi Li,Honglin Zhu,Fangping Zhao,Jinlei Ding,Yunshu Zhu,Sizhen Wang,Guochen Sun,Hongbin Ni,Tonghui Ma,Ting Lei
标识
DOI:10.1016/j.jgg.2021.12.012
摘要
Li-Fraumeni syndrome (LFS), a rare autosomal-dominant inheritance condition, is associated with a family cancer history as well as pathogenic/likely-pathogenic TP53 germline variants (P/LP TP53 GV). The current clinical methods for detecting LFS are limited. Here, we retrospectively investigate P/LP TP53 GV among Chinese cancer patients by next-generation sequencing and evaluate its relationship with a family cancer history. A total of 270 out of 19,226 cancer patients have TP53 GV, including 53 patients with P/LP TP53 GV. Patients with P/LP TP53 GV are mainly found in male with glioma, lung cancer or sarcoma. The median age of diagnosis for P/LP TP53 GV patients is significantly lower than that of non-P/LP TP53 GV patients (31-years vs. 53-years; P < 0.01). One LFS patient and 3 Li-Fraumeni-like syndrome (LFL) patients are among the 26 followed-up P/LP TP53 GV patients. Among 25 types of P/LP TP53 GV, the highest variant frequencies occurred at codon 175 and 248. p.M237I, p.R158H, p.C238Y and p.C275R, are firstly identified among the Chinese LFS/LFL patients. This study reports the (P/LP) TP53 GV characteristics of Chinese pan-cancer patients. These findings suggest analyzing the P/LP TP53 GV in cancer patients is an effective strategy for identifying cancer predisposition syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI